MONTREAL, Sept. 3, 2024 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that it has entered into an agreement (the "Amendment") with Sagard Healthcare Royalty Partners, LP ("Sagard"), which amends the Secured Term Loan (the "Facility'') entered into between Valeo and Sagard in July 2022.
Read more at newswire.cahello world
Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.
